Phase II study of weekly oxaliplatin and 24-h infusion of high-dose 5-fluorouracil and folinic acid in the treatment of advanced gastric cancer

Y. Chao, K. H. Yeh, C. J. Chang, L. T. Chen, T. Y. Chao, M. F. Wu, C. S. Chang, J. Y. Chang, C. Y. Chung, W. Y. Kao, R. K. Hsieh, A. L. Cheng

Research output: Contribution to journalArticle

70 Citations (Scopus)

Abstract

To investigate the efficacy and safety of combining weekly oxaliplatin with weekly 24-h infusion of high-dose 5-fluorouracil (5-FU) and folinic acid (FA) in treatment of patients with advanced gastric cancer. Patients with histologically confirmed, locally advanced or recurrent/metastatic gastric cancer were studied. Oxaliplatin 65 mg m-2 2-h intravenous infusion, and 5-FU 2600 mg m-2 plus FA 300 mg m-2 24-h intravenous infusion, were given on days 1 and 8, repeated every 3 weeks. Between January 2001 through January 2002, 55 patients were enrolled. The median age was 64 years (range: 22-75). In all, 52 patients (94.5%) had recurrent or metastatic disease and three patients had locally advanced disease. Among 50 patients evaluable for tumour response, 28 patients achieved partial response, with an overall response rate of 56% (95% confidence interval (CI): 41.8-70.3%). All 55 patients were evaluated for survival and toxicities. Median time to progression and overall survival were 5.2 and 10.0 months, respectively, during median follow-up time of 24.0 months. Major grades 3-4 toxicities were neutropenia in 23 cycles (7.1%) and thrombocytopenia in 16 cycles (5.0%). Treatment was discontinued for treatment-related toxicities in nine patients (16.4%), of whom eight were due to oxaliplatin-related neurotoxicity. One patient (1.8%) died of neutropenic sepsis. This oxalipiatin-containing regimen is effective in the treatment of advanced gastric cancer. Except for neurotoxicity that often develops after prolonged use of oxaliplatin, the regimen is well tolerated.

Original languageEnglish
Pages (from-to)453-458
Number of pages6
JournalBritish Journal of Cancer
Volume91
Issue number3
DOIs
Publication statusPublished - Aug 2 2004
Externally publishedYes

Fingerprint

oxaliplatin
Leucovorin
Fluorouracil
Stomach Neoplasms
Therapeutics
Intravenous Infusions

Keywords

  • Advanced gastric cancer
  • Folinic acid
  • High-dose 5-fluorouracil
  • Oxaliplatin

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Phase II study of weekly oxaliplatin and 24-h infusion of high-dose 5-fluorouracil and folinic acid in the treatment of advanced gastric cancer. / Chao, Y.; Yeh, K. H.; Chang, C. J.; Chen, L. T.; Chao, T. Y.; Wu, M. F.; Chang, C. S.; Chang, J. Y.; Chung, C. Y.; Kao, W. Y.; Hsieh, R. K.; Cheng, A. L.

In: British Journal of Cancer, Vol. 91, No. 3, 02.08.2004, p. 453-458.

Research output: Contribution to journalArticle

Chao, Y, Yeh, KH, Chang, CJ, Chen, LT, Chao, TY, Wu, MF, Chang, CS, Chang, JY, Chung, CY, Kao, WY, Hsieh, RK & Cheng, AL 2004, 'Phase II study of weekly oxaliplatin and 24-h infusion of high-dose 5-fluorouracil and folinic acid in the treatment of advanced gastric cancer', British Journal of Cancer, vol. 91, no. 3, pp. 453-458. https://doi.org/10.1038/sj.bjc.6601985
Chao, Y. ; Yeh, K. H. ; Chang, C. J. ; Chen, L. T. ; Chao, T. Y. ; Wu, M. F. ; Chang, C. S. ; Chang, J. Y. ; Chung, C. Y. ; Kao, W. Y. ; Hsieh, R. K. ; Cheng, A. L. / Phase II study of weekly oxaliplatin and 24-h infusion of high-dose 5-fluorouracil and folinic acid in the treatment of advanced gastric cancer. In: British Journal of Cancer. 2004 ; Vol. 91, No. 3. pp. 453-458.
@article{d646f1ce554a40ee8bcc7b2ef4029b79,
title = "Phase II study of weekly oxaliplatin and 24-h infusion of high-dose 5-fluorouracil and folinic acid in the treatment of advanced gastric cancer",
abstract = "To investigate the efficacy and safety of combining weekly oxaliplatin with weekly 24-h infusion of high-dose 5-fluorouracil (5-FU) and folinic acid (FA) in treatment of patients with advanced gastric cancer. Patients with histologically confirmed, locally advanced or recurrent/metastatic gastric cancer were studied. Oxaliplatin 65 mg m-2 2-h intravenous infusion, and 5-FU 2600 mg m-2 plus FA 300 mg m-2 24-h intravenous infusion, were given on days 1 and 8, repeated every 3 weeks. Between January 2001 through January 2002, 55 patients were enrolled. The median age was 64 years (range: 22-75). In all, 52 patients (94.5{\%}) had recurrent or metastatic disease and three patients had locally advanced disease. Among 50 patients evaluable for tumour response, 28 patients achieved partial response, with an overall response rate of 56{\%} (95{\%} confidence interval (CI): 41.8-70.3{\%}). All 55 patients were evaluated for survival and toxicities. Median time to progression and overall survival were 5.2 and 10.0 months, respectively, during median follow-up time of 24.0 months. Major grades 3-4 toxicities were neutropenia in 23 cycles (7.1{\%}) and thrombocytopenia in 16 cycles (5.0{\%}). Treatment was discontinued for treatment-related toxicities in nine patients (16.4{\%}), of whom eight were due to oxaliplatin-related neurotoxicity. One patient (1.8{\%}) died of neutropenic sepsis. This oxalipiatin-containing regimen is effective in the treatment of advanced gastric cancer. Except for neurotoxicity that often develops after prolonged use of oxaliplatin, the regimen is well tolerated.",
keywords = "Advanced gastric cancer, Folinic acid, High-dose 5-fluorouracil, Oxaliplatin",
author = "Y. Chao and Yeh, {K. H.} and Chang, {C. J.} and Chen, {L. T.} and Chao, {T. Y.} and Wu, {M. F.} and Chang, {C. S.} and Chang, {J. Y.} and Chung, {C. Y.} and Kao, {W. Y.} and Hsieh, {R. K.} and Cheng, {A. L.}",
year = "2004",
month = "8",
day = "2",
doi = "10.1038/sj.bjc.6601985",
language = "English",
volume = "91",
pages = "453--458",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Phase II study of weekly oxaliplatin and 24-h infusion of high-dose 5-fluorouracil and folinic acid in the treatment of advanced gastric cancer

AU - Chao, Y.

AU - Yeh, K. H.

AU - Chang, C. J.

AU - Chen, L. T.

AU - Chao, T. Y.

AU - Wu, M. F.

AU - Chang, C. S.

AU - Chang, J. Y.

AU - Chung, C. Y.

AU - Kao, W. Y.

AU - Hsieh, R. K.

AU - Cheng, A. L.

PY - 2004/8/2

Y1 - 2004/8/2

N2 - To investigate the efficacy and safety of combining weekly oxaliplatin with weekly 24-h infusion of high-dose 5-fluorouracil (5-FU) and folinic acid (FA) in treatment of patients with advanced gastric cancer. Patients with histologically confirmed, locally advanced or recurrent/metastatic gastric cancer were studied. Oxaliplatin 65 mg m-2 2-h intravenous infusion, and 5-FU 2600 mg m-2 plus FA 300 mg m-2 24-h intravenous infusion, were given on days 1 and 8, repeated every 3 weeks. Between January 2001 through January 2002, 55 patients were enrolled. The median age was 64 years (range: 22-75). In all, 52 patients (94.5%) had recurrent or metastatic disease and three patients had locally advanced disease. Among 50 patients evaluable for tumour response, 28 patients achieved partial response, with an overall response rate of 56% (95% confidence interval (CI): 41.8-70.3%). All 55 patients were evaluated for survival and toxicities. Median time to progression and overall survival were 5.2 and 10.0 months, respectively, during median follow-up time of 24.0 months. Major grades 3-4 toxicities were neutropenia in 23 cycles (7.1%) and thrombocytopenia in 16 cycles (5.0%). Treatment was discontinued for treatment-related toxicities in nine patients (16.4%), of whom eight were due to oxaliplatin-related neurotoxicity. One patient (1.8%) died of neutropenic sepsis. This oxalipiatin-containing regimen is effective in the treatment of advanced gastric cancer. Except for neurotoxicity that often develops after prolonged use of oxaliplatin, the regimen is well tolerated.

AB - To investigate the efficacy and safety of combining weekly oxaliplatin with weekly 24-h infusion of high-dose 5-fluorouracil (5-FU) and folinic acid (FA) in treatment of patients with advanced gastric cancer. Patients with histologically confirmed, locally advanced or recurrent/metastatic gastric cancer were studied. Oxaliplatin 65 mg m-2 2-h intravenous infusion, and 5-FU 2600 mg m-2 plus FA 300 mg m-2 24-h intravenous infusion, were given on days 1 and 8, repeated every 3 weeks. Between January 2001 through January 2002, 55 patients were enrolled. The median age was 64 years (range: 22-75). In all, 52 patients (94.5%) had recurrent or metastatic disease and three patients had locally advanced disease. Among 50 patients evaluable for tumour response, 28 patients achieved partial response, with an overall response rate of 56% (95% confidence interval (CI): 41.8-70.3%). All 55 patients were evaluated for survival and toxicities. Median time to progression and overall survival were 5.2 and 10.0 months, respectively, during median follow-up time of 24.0 months. Major grades 3-4 toxicities were neutropenia in 23 cycles (7.1%) and thrombocytopenia in 16 cycles (5.0%). Treatment was discontinued for treatment-related toxicities in nine patients (16.4%), of whom eight were due to oxaliplatin-related neurotoxicity. One patient (1.8%) died of neutropenic sepsis. This oxalipiatin-containing regimen is effective in the treatment of advanced gastric cancer. Except for neurotoxicity that often develops after prolonged use of oxaliplatin, the regimen is well tolerated.

KW - Advanced gastric cancer

KW - Folinic acid

KW - High-dose 5-fluorouracil

KW - Oxaliplatin

UR - http://www.scopus.com/inward/record.url?scp=4243135036&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4243135036&partnerID=8YFLogxK

U2 - 10.1038/sj.bjc.6601985

DO - 10.1038/sj.bjc.6601985

M3 - Article

C2 - 15226770

AN - SCOPUS:4243135036

VL - 91

SP - 453

EP - 458

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 3

ER -